Opioid marketing scrutinised by TGA, questioned by RACGP The Therapeutic Goods Administration has confirmed it is examining opioid marketing material aimed at GPs.
What should GPs know about bioidentical hormone therapy? Two experts answer common questions on compounding bioidentical hormone therapy for menopause.
Food labelling: When is a medicine not a medicine? Concerns have been raised over alleged double standards regarding the regulation of food products promoted as having ‘special medical purposes’.
TGA criticised over lack of safety warnings Questions have been raised over the way Australia’s therapeutic regulator is informing doctors and patients about potentially dangerous drugs.
Codeine supply in Australia has almost halved The massive decrease has been attributed to the 2018 decision to up-schedule codeine to a Schedule 4 prescription-only medicine.
Why down-scheduling medicines is fraught with danger Assoc Prof Mark Morgan questions whether a push to make more prescription-only medicines available over the counter is best for patients.
Safety concerns over popular arthritis drug The TGA issued an alert after a study found high doses of tofacitinib could lead to increased risk of blood clots in the lungs and potentially death.
TGA moves to ease fears over a ‘no deal’ Brexit Imported medicines and devices will be minimally affected under a ‘no deal’ Brexit, according to the Therapeutic Goods Administration.
Commercial sensitivity or patient protection? Secrecy and medicine safety Researchers have identified an information gap between pharmacological companies and Australian clinicians on the potential safety risks of medicines.
The good, the bad and the dangerous: Advising on healthcare apps How can GPs and patients distinguish the helpful from the useless – or even harmful – among the ever-increasing flood of healthcare apps?